ClinicalTrials.gg
RecruitingNCT06280378Updated Nov 2, 2026

β-Thalassemia Treatment With KL003 Cell Injection

A Phase 1/2 interventional study of KL003 Cell Injection Drug Product in Transfusion-dependent Beta-Thalassemia, sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
3 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
7th of 34
41 · median 10
Started
2024
with 10 others
Phase 1/2
5 of 44
1 open now
Primary completion
2027-11
later than 13 of 24 live
Registered
31st of 44
by date

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 7th largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 13 of the 24 other live ones, and was the 31st registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.

Read the detailed description

This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. KL003 Cell Injection is autologous CD34+ stem cells transduced Ex Vivo with a lentiviral Vector encoding βA-T87Q-Globin.

03

Conditions studied

  • Transfusion-dependent Beta-Thalassemia

Browse trials for

Keywords

  • gene therapy
  • lentiviral vector
  • KL003 cell injection
  • transfusion-dependent β-thalassemia
04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age between 3-35 years;
  • Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years;
  • performance status ≥70 for participants≥16 years of age; Lansky performance status of ≥70 for participants\<16 years of age;
  • Eligible to undergo ;
  • Willing and able to follow the research procedures and conditions, with good compliance;
  • Willing to receive at least the 2 years follow-up;
  • Participant and/or legal guardians voluntarily participated in this clinical trial and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of composite α thalassemia;
  • Prior receipt of gene therapy or ;
  • Meet the criteria for allo-HSCT and with an identified willing donor with full HLA match;
  • Participants with severe iron overload at the time of screening;
  • Presence of unusual antibody of red blood cell antigens or tested positive for antibody;
  • Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.);
  • and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator;
  • Subjects positive with the following etiological tests: (HIV-1-2),human cytomegalovirus (HCMV-DNA),EB virus(EBV-DNA), (HBsAg/HBV-DNA positive), antibody (HCV-Ab), Human T-lymphotropic virus antibody (HTLV-Ab), Treponema pallidum antibody (TP-Ab);
  • Uncorrectable coagulation dysfunction or history of severe bleeding disorder;
  • History of major organ damage including:

    1. Liver function test suggest or ALT levels >3× (ULN);
    2. Total serum value>2.5×ULN;if combined with Gilbert syndrome, total bilirubin>3×ULN and direct bilirubin value>2.5×ULN;
    3. \<45%;
    4. Baseline calculated \<60mL/min/1.73m2;
    5. Pulmonary function:/FVC\<60% and/or diffusion capacity of carbon monoxide (DLco) \<60% of prediction;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    KL003 Cell Injection Drug Product

    Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene

    Drug: KL003 Cell Injection Drug Product

Interventions

  • DrugKL003 Cell Injection Drug Product

    Administered by intravenous infusion after myeloablative conditioning with busulfan.

06

What researchers measure

Primary outcomes

  1. KL003 engraftment

    Proportion of participants with successful engraftment within 42 days after KL003 infusion.

    Time frame: From time of KL003 infusion through Month 2

  2. Engraftment time of neutrophil and platelet

    Neutrophil engraftment was defined as the first day when neutrophils ≥ 0.5×10\^9/L for 3 consecutive days; Platelet engraftment was defined as the first the first day of platelet count ≥ 20.0×10\^9/L for 7 consecutive days with no platelet transfusions.

    Time frame: From time of KL003 infusion through Month 24

  3. Overall Survival

    Overall survival was defined as time from date of KL003 infusion to date of death.

    Time frame: From time of KL003 infusion through Month 24

  4. The number, frequency and severity of adverse events (AE) within 1 year after infusion of KL003 drug products

    Frequency and severity of AEs \& SAEs identified according to NCI CTCAE 5.0

    Time frame: From time of KL003 infusion through Month 24

  5. Clonal dominance or secondary tumors caused by lentiviral vector insertional-mutation

    Clonal dominance was defined as an ISA result greater than 90% of the total insertion sites (IS) at any time

    Time frame: From time of KL003 infusion through Month 24

  6. Numbers of Participants With Vector-Derived Replication-Competent Lentivirus (RCL)

    Peripheral blood samples were analyzed for detection of RCL

    Time frame: From time of KL003 infusion through Month 24

Secondary outcomes

  1. The proportion of participants achieved Transfusion Independence (TI)for at least 6 months

    TI 6 is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months

    Time frame: From time of KL003 infusion through Month 24

  2. The proportion of participants achieved TI 12

    TI 12 is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 12 months

    Time frame: From time of KL003 infusion through Month 24

  3. The start time of Transfusion Independence (TI) after KL003 infusion

    The TI start time is defined as the first day of treated participants with transfusion-dependent β-thalassemia (TDT) who achieved transfusion independence.

    Time frame: From time of KL003 infusion through Month 24

  4. Total Hb and the vector-derived HbA^T87Q

    The total Hb is measured by routine blood test, Therapeutic globin expression was measured by HbA\^T87Q in peripheral blood.

    Time frame: From time of KL003 infusion through Month 24

07

Study locations

2 of 2 sites recruiting
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Wei Tang, PhD · Contact+86 13472889588
    • Saijuan Chen, PhD · Principal investigator
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Zhen Gao, Master · ContactGaozhen@ihcams.ac.cn · +86 15522360862
    • Jun Shi, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2024 (actual). Primary completion is estimated for Nov 2027, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Oct 2025 → Nov 2027 and completion May 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
Apr 5, 2024
Primary completionEst.
Nov 20, 2027was Oct 2025
CompletionEst.
Dec 20, 2028was May 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 China)
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine · Shanghai, China
  • Institute of Hematology & Blood Diseases Hospital · Tianjin, China
Show 2 removed
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine · Shanghai, China
  • Institute of Hematology & Blood Diseases Hospital · Tianjin, China
Nov 2, 2026
Primary completion
Oct 2025→Nov 20, 2027
Nov 2, 2026
Study completion
May 2027→Dec 20, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 China)
    • Ruijin Hospital, Shanghai Jiaotong University School of Medicine · Shanghai, China
    • Institute of Hematology & Blood Diseases Hospital · Tianjin, China
    Show 2 removed
    • Ruijin Hospital, Shanghai Jiaotong University School of Medicine · Shanghai, China
    • Institute of Hematology & Blood Diseases Hospital · Tianjin, China
    Primary completion Oct 2025→Nov 20, 2027
    Study completion May 2027→Dec 20, 2028
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06280378
Lead sponsor
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Apr 5, 2024
Primary completion
Nov 20, 2027 (estimated)
Completion
Dec 20, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

jingfeng Yan
Contact
yanjingfeng@kanglinbio.com
+86 18852138866
Haoquan Wu, PhD
study director · R&D Kanglin Biotech

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion